NAV

Technetium Tc-99m nofetumomab merpentan

Identification

Generic Name
Technetium Tc-99m nofetumomab merpentan
DrugBank Accession Number
DB09336
Background

Technetium Tc-99m nofetumomab merpentan (Tc-99m nm) consists of a Fab fragment of an IgG2b of the pancarcinoma murine antibody NR-LU-10.1 The NR-LU-10 antibody is directed against a 40 kDa glycoprotein antigen expressed in a variety of cancers and some normal tissues.Label Tc-99m nm was developed by Boehringer Ingelheim Pharma KG and FDA approved on September 14, 1992. It was after discontinued on August 13, 2013, but in the 2018 FDA submission list, it can be found as a substance type II (Drug substance) with an active status.8,9

Type
Small Molecule
Groups
Approved, Withdrawn
Synonyms
  • Nofetumomab
  • Technetium (99mTc) nofetumomab merpentan
  • Technetium Tc 99m nofetumomab merpentan
Poor quality drug data slowing you down?
Unlock 38% more drug discovery time and eliminate decision-making doubts with this one-stop guide to quality drug data.
Download eBook
Poor quality drug data slowing you down?
Download eBook

Pharmacology

Indication

Tc-99m nm is one of the technetium-labeled antibodies and it is indicated for the detection of small-cell lung cancer.3 The small cell lung cancer is a syndrome characterized by the abnormal and uncontrolled cell growth and it is characterized by a shorter doubling time, higher growth fraction and earlier development of metastases.4

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Studies have shown that the Fab fragment presents high immunoreactivity in small cell lung cancer tumors. The adenocarcinomas of the kidney and pancreas are not detected. This lack of diagnostic detection can be explained because some radioactivity gets accumulated in the excretion pathway, in nonspecific vascular locations and in non-tumor areas with traces of inflammation, increased vascular pool or recent surgical. Therefore, the detection rate may be reduced in those areas and its adjacent zones.Label

Mechanism of action

The mechanism of action in Tc-99m nm is ruled by the presence of nofetumomab, which can recognize the pancarcinoma antigen EpCAM and/or CD20/MS4A1,2 and merpentan, that acts as a linker for the binding of technetium.6

TargetActionsOrganism
AEpithelial cell adhesion molecule
binder
Humans
AB-lymphocyte antigen CD20
binder
Humans
Absorption

After intravenous administration, Tc-99m nm presents a rapid distribution phase.Label

Volume of distribution

Not Available

Protein binding

There are no reports of binding of Tc-99m nm to binding proteins.Label

Metabolism
Not Available
Route of elimination

The primary route of elimination is renal and accounts for the 64% of the administered dose. After renal clearance, the main route is hepatobiliary. All the different elimination pathways lead to accumulation of radioactivity on the kidney, urinary bladder, gall bladder and intestines.7

Half-life

The radioactive half-life of the Tc-99m nm is of 6 hours. It is important to consider this short half-life as the use of this agent should be done within the active time.5 Tc-99m nm presents a serum half-life of 1.5 hours and an elimination phase half-life of 10.5 hours.7

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Long-term preclinical studies to determine the carcinogenic, mutagenic or fertility effect have not been studied.Label

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Categories

Drug Categories
Classification
Not classified
Affected organisms
  • Humans and other mammals

Chemical Identifiers

UNII
9UFH75HT7S
CAS number
165942-79-0
InChI Key
Not Available
InChI
Not Available
IUPAC Name
Not Available
SMILES
Not Available

References

General References
  1. Breitz HB, Tyler A, Bjorn MJ, Lesley T, Weiden PL: Clinical experience with Tc-99m nofetumomab merpentan (Verluma) radioimmunoscintigraphy. Clin Nucl Med. 1997 Sep;22(9):615-20. [Article]
  2. Honjo T., Alt F. and Neuberger M. (2004). Molecular biology of B cells. Elsevier .
  3. Technetium radiopharmaceutical chemistry [Link]
  4. Cancer [Link]
  5. Pharmacopeia [Link]
  6. Pharmacological science [Link]
  7. National Public library [Link]
  8. FDA CDER list [Link]
  9. FDA Submission [Link]
PubChem Substance
347910442
FDA label
Download (1.32 MB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
Radioactivity (mCi/mL)30FDA label
Predicted Properties
Not Available
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available
Chromatographic Properties
Collision Cross Sections (CCS)
Not Available

Targets

Build, predict & validate machine-learning models
Use our structured and evidence-based datasets to unlock new
insights and accelerate drug research.
Learn more
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
Learn more
Details1. Epithelial cell adhesion molecule
Kind
Protein
Organism
Humans
Pharmacological action
Yes
Actions
Binder
General Function
Protein complex binding
Specific Function
May act as a physical homophilic interaction molecule between intestinal epithelial cells (IECs) and intraepithelial lymphocytes (IELs) at the mucosal epithelium for providing immunological barrier...
Gene Name
EPCAM
Uniprot ID
P16422
Uniprot Name
Epithelial cell adhesion molecule
Molecular Weight
34932.005 Da
References
  1. Honjo T., Alt F. and Neuberger M. (2004). Molecular biology of B cells. Elsevier .
Details2. B-lymphocyte antigen CD20
Kind
Protein
Organism
Humans
Pharmacological action
Yes
Actions
Binder
General Function
Mhc class ii protein complex binding
Specific Function
This protein may be involved in the regulation of B-cell activation and proliferation.
Gene Name
MS4A1
Uniprot ID
P11836
Uniprot Name
B-lymphocyte antigen CD20
Molecular Weight
33076.99 Da
References
  1. Honjo T., Alt F. and Neuberger M. (2004). Molecular biology of B cells. Elsevier .

Drug created at November 27, 2015 00:09 / Updated at June 12, 2020 16:52